GRAIL Inc - GRAL Company Long-Term Liabilities

The GRAL asset's market trend, analyzed on the price chart, is based on the use of automated US laboratories to analyze Galleri tests, with the indicator being 0.07. Financial sustainability is low due to colossal expenditures on promotion and research, while generating no profit. Growth prospects depend on the product's acceptance by insurance companies, as a stable cash flow has not yet been established.

GRAL (grail.com) Company Long-Term Debt history from 06/29/2024 to 10/28/2026

GRAIL Corp (GRAL) - metric breakdowns and financial figures

- price and consensus price forecast:

Share Price grail.com|GRAL - Analyst Consensus Forecast

- market capitalization data:

Market Valuation GRAIL|GRAL - Enterprise Value

- book capitalization data:

Net Asset Value per Share GRAIL|GRAL - Company Book Value|Market Value to Book Value grail.com|GRAL - Cumulative Company Assets

- debt and liquidity data:

Initial company analysis:GRAL (grail.com)

When constructing a long-term portfolio, it is critical to assess capital structure stability by analyzing liabilities with maturities exceeding one year. This metric measures the volume of borrowed funds required by GRAIL, Inc. (GRAL) to scale the implementation of Galleri AI diagnostics, making the monitoring of the company's long-term debt a key tool for evaluating financial leverage and risks during macroeconomic shocks.

Who GRAIL, Inc. competes with

Company Long-Term Indebtedness carislifesciences.com CAI|GH: Company Long-Term Debts|VCYT - Company Long-Term Liabilities|Company Long-Term Debts CELC|MYGN (Myriad) - Long-Term Debt|CSTL - Company Long-Term Debt|Company Long-Term Loans and Borrowings brbiotech.com (BNR)|VolitionRx Limited (VNRX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Biodesix Inc (BDSX)|Company Long-Term Debts PRPO (Precipio, Inc)|Check-Cap Ltd - Company Long-Term Debts|Mainz Biomed N.V. (MYNZ) - Company Long-Term Debt|OCX - Company Long-Term Indebtedness